The data set spanning 99 million people did not include patients from India; a majority of Indians were administered the ChAdOX1 or Covishield vaccines during the pandemic
Boxes of the Oxford/AstraZeneca (ChadOX1) COVID-19 vaccine are
pictured in a refrigerator at a vaccination centre in Hertfordshire, Britain on
January 11, 2021.
One of the largest assessments of its kind, spanning 99 million
people and investigating reports of adverse reactions following COVID-19
vaccination, found that instances of Guillain Barre Syndrome, myocarditis,
pericarditis and cerebral venous sinus thrombosis (CVST) were at least 1.5
times more than expected following inoculation with mRNA and ChadOX1 vaccines.
This is in line with previous observations by the World Health Organization and
the European Medicines Agency, and was what led to these being classified as
‘rare’ side effects following the vaccination for COVID-19.
The data set did not include patients from India. However, a majority of Indians were administered the ChAdOX1 or Covishield vaccines during the pandemic. The need for rapid development and administration of vaccines saw a range of new approaches to vaccination, namely, the use of synthetic viral particles or protein constructs being administered following shortened testing programmes.
No comments:
Post a Comment